Coherus Biosciences filed a petition at the US Patent and Trademark Office last week, seeking to cancel the claims of U.S. Patent 8,163,522 (the ’522 patent), entitled “Human TNF Receptor,” and assigned on its face to Hoffman-LaRoche Inc. According to a Coherus press release, the ’522 patent is controlled by Amgen and is generally directed to a method for making etanercept, the active pharmaceutical ingredient of Enbrel®. In its petition, Coherus noted that it is “developing for U.S. regulatory approval and commercial introduction an etanercept product for the treatment of disorders such as rheumatoid arthritis.”
The petition and other selected PTAB filings concerning biologics are posted on our IPR Tracker Page.
The post COHERUS BIOSCIENCES PETITIONS FOR IPR OF PATENT RELATED TO ENBREL appeared first on Goodwin Procter BioSimilars Blog.